Natco Pharma's Q4 Profit Jumps on Strong Margins, Capping a Stellar Year
Natco Pharma's profit soared 78% sequentially in Q4, with net profit margin hitting 36.4%, even as annual revenue and profit grew strongly.
Natco Pharma delivered a robust sequential recovery in Q4 FY26, with profit up 78% and net profit margin expanding significantly. The full-year results show strong double-digit growth.
Natco Pharma's fourth-quarter results present a tale of two trends: a sharp sequential recovery in profitability against a challenging year-on-year comparison. The company's profit after tax jumped 77.8% from the previous quarter, driven by a significant expansion in net profit margin to 36.4%. This strong finish helped cement a powerful full-year performance, with annual profit surging 35.8% on a 10.8% rise in revenue.
The quarterly story is one of resilience. While revenue of ₹739.1 crore was down 39.5% from the same quarter last year, profitability held up remarkably well. Profit declined by a smaller 33.7% year-on-year, and the net profit margin actually improved by 310 basis points. This indicates effective cost management and a favorable product mix during the period. The sequential momentum is clear, with both revenue and profit rebounding strongly from a softer Q3.
Revenue (₹ Cr)
Profit (₹ Cr)
Net Profit Margin (%)
| Metric | CurrentQ4 FY26 | PreviousQ3 FY26 | Same quarter LYQ4 FY25 |
|---|---|---|---|
| Revenue (₹ Cr) | 739.1YoY -39% | 647.3 | 1221.0 |
| Profit (₹ Cr) | 269.0YoY -34% | 151.3 | 406.0 |
| Net Profit Margin (%) | 36.4YoY +9.3% | 23.4 | 33.3 |
Looking at the full year, the strength of Natco's business model is evident. The company closed FY25 with revenue of ₹4,429.5 crore and a formidable net profit margin of 42.6%. This caps a period of exceptional long-term growth, with profit compounding at an annual rate of 123% over the past five years.
Key Points
- The company maintains a rock-solid balance sheet, with a debt-to-equity ratio of just 0.04 and a high interest coverage of 96.87.
- Shareholder returns remain strong, evidenced by a Return on Equity (ROE) of 27.98%.
- The stock has delivered impressive returns, gaining 45.6% over the past year and 90.2% over three years.
Despite this operational strength and stellar share price performance, Natco Pharma trades at a significant discount to its industry, with a P/E of 7.6 compared to the sector average of 37.0. The focus now shifts to whether the company can sustain its high profitability and translate its Q4 sequential momentum into consistent quarterly performance.
Live Chart
· NATCOPHARM
(BSE)
ISIN: INE987B01026
Also read
Want this applied to your portfolio?
Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.